Novartis AG

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH0012005267
CHF
119.14
-0.38 (-0.32%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.96 M

Shareholding (Dec 2025)

FII

0.04%

Held by 12 FIIs

DII

99.96%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor long term growth as Net Sales has grown by an annual rate of -0.15% over the last 5 years

 
2

With ROE of 39.74%, it has a Very Expensive valuation with a 6.58 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CHF 255,265 Million ()

stock-summary
P/E

17.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.29

stock-summary
Return on Equity

33.71%

stock-summary
Price to Book

6.98

Revenue and Profits:
Net Sales:
10,658 Million
(Quarterly Results - Dec 2025)
Net Profit:
1,921 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.21%
0%
8.21%
6 Months
21.08%
0%
21.08%
1 Year
21.21%
0%
21.21%
2 Years
37.48%
0%
37.48%
3 Years
52.83%
0%
52.83%
4 Years
55.75%
0%
55.75%
5 Years
53.52%
0%
53.52%

Novartis AG for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-0.15%
EBIT Growth (5y)
7.58%
EBIT to Interest (avg)
14.48
Debt to EBITDA (avg)
0.60
Net Debt to Equity (avg)
0.59
Sales to Capital Employed (avg)
0.60
Tax Ratio
13.85%
Dividend Payout Ratio
61.77%
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
19.87%
ROE (avg)
25.50%

Valuation key factors

Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
6.58
EV to EBIT
16.13
EV to EBITDA
11.99
EV to Capital Employed
4.55
EV to Sales
5.18
PEG Ratio
0.97
Dividend Yield
NA
ROCE (Latest)
28.21%
ROE (Latest)
39.74%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 12 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -4.24% vs -4.22% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -38.91% vs -5.48% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10,658.40",
          "val2": "11,130.20",
          "chgp": "-4.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4,053.70",
          "val2": "4,373.20",
          "chgp": "-7.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "243.00",
          "val2": "224.90",
          "chgp": "8.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-421.20",
          "val2": "-71.20",
          "chgp": "-491.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,921.30",
          "val2": "3,144.90",
          "chgp": "-38.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "264.00%",
          "val2": "302.40%",
          "chgp": "-3.84%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 2.20% vs 8.52% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 10.32% vs 36.49% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "45,288.10",
          "val2": "44,312.50",
          "chgp": "2.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "18,529.80",
          "val2": "18,930.80",
          "chgp": "-2.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "980.80",
          "val2": "913.30",
          "chgp": "7.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-949.20",
          "val2": "-1,696.20",
          "chgp": "44.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "11,599.40",
          "val2": "10,514.30",
          "chgp": "10.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "311.50%",
          "val2": "306.60%",
          "chgp": "0.49%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
10,658.40
11,130.20
-4.24%
Operating Profit (PBDIT) excl Other Income
4,053.70
4,373.20
-7.31%
Interest
243.00
224.90
8.05%
Exceptional Items
-421.20
-71.20
-491.57%
Consolidate Net Profit
1,921.30
3,144.90
-38.91%
Operating Profit Margin (Excl OI)
264.00%
302.40%
-3.84%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -4.24% vs -4.22% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -38.91% vs -5.48% in Sep 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
45,288.10
44,312.50
2.20%
Operating Profit (PBDIT) excl Other Income
18,529.80
18,930.80
-2.12%
Interest
980.80
913.30
7.39%
Exceptional Items
-949.20
-1,696.20
44.04%
Consolidate Net Profit
11,599.40
10,514.30
10.32%
Operating Profit Margin (Excl OI)
311.50%
306.60%
0.49%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 2.20% vs 8.52% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 10.32% vs 36.49% in Dec 2024

stock-summaryCompany CV
About Novartis AG stock-summary
stock-summary
Novartis AG
Pharmaceuticals & Biotechnology
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Company Coordinates stock-summary
Company Details
Lichtstrasse 35 , BASEL None : 4056
stock-summary
Tel: 41 61 3241111
stock-summary
Registrar Details